Healthcare provider profile · identity verified

Christopher A. Campagnari, MD

Family Practice · HOPE VALLEY, RI · NPI 1992771562

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	442	106
Amlodipine Besylate	Amlodipine Besylate	357	92
Lisinopril	Lisinopril	315	75
Levothyroxine Sodium	Levothyroxine Sodium	297	66
Omeprazole	Omeprazole	270	70
Metformin Hcl	Metformin Hcl	222	51
Albuterol Sulfate Hfa	Albuterol Sulfate	209	70
Simvastatin	Simvastatin	190	47
Montelukast Sodium	Montelukast Sodium	182	40
Gabapentin	Gabapentin	175	38
Metoprolol Succinate	Metoprolol Succinate	145	43
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	141	26
Jardiance	Empagliflozin	130	28
Oxycodone Hcl	Oxycodone Hcl	129	21
Losartan Potassium	Losartan Potassium	125	33
Metformin Hcl Er	Metformin Hcl	112	26
Tamsulosin Hcl	Tamsulosin Hcl	108	25
Azelastine Hcl	Azelastine Hcl	91	29
Clonazepam	Clonazepam	86	12
Pravastatin Sodium	Pravastatin Sodium	86	13
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	82	24
Rosuvastatin Calcium	Rosuvastatin Calcium	82	22
Pantoprazole Sodium	Pantoprazole Sodium	77	17
Escitalopram Oxalate	Escitalopram Oxalate	76	18
Allopurinol	Allopurinol	75	18
Ozempic	Semaglutide	75	11
Fluticasone Propionate	Fluticasone Propionate	74	26
Tramadol Hcl	Tramadol Hcl	73	15
Meloxicam	Meloxicam	71	23
Metoprolol Tartrate	Metoprolol Tartrate	70	17
Sertraline Hcl	Sertraline Hcl	68	15
Glipizide	Glipizide	61	19
Furosemide	Furosemide	60	19
Pregabalin	Pregabalin	59	13
Famotidine	Famotidine	58	17
Duloxetine Hcl	Duloxetine Hcl	57	16
Venlafaxine Hcl Er	Venlafaxine Hcl	56	suppressed
Alprazolam	Alprazolam	52	suppressed
Chlorthalidone	Chlorthalidone	51	13
Clopidogrel	Clopidogrel Bisulfate	49	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	49	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	48	15
Potassium Chloride	Potassium Chloride	46	14
Benazepril Hcl	Benazepril Hcl	45	suppressed
Bupropion Xl	Bupropion Hcl	45	suppressed
Lorazepam	Lorazepam	45	16
Prazosin Hcl	Prazosin Hcl	43	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	41	suppressed
Mirtazapine	Mirtazapine	40	suppressed
Ventolin Hfa	Albuterol Sulfate	40	suppressed
Eliquis	Apixaban	38	12
Fluoxetine Hcl	Fluoxetine Hcl	37	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	36	suppressed
Celecoxib	Celecoxib	36	suppressed
Ibuprofen	Ibuprofen	36	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	36	suppressed
Arnuity Ellipta	Fluticasone Furoate	35	11
Prednisone	Prednisone	35	26
Atenolol	Atenolol	34	suppressed
Nystatin	Nystatin	34	14
Xarelto	Rivaroxaban	32	suppressed
Carvedilol	Carvedilol	31	suppressed
Buspirone Hcl	Buspirone Hcl	30	suppressed
Naproxen	Naproxen	30	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	26	suppressed
Lovastatin	Lovastatin	26	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	25	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	25	suppressed
Ezetimibe	Ezetimibe	24	suppressed
Farxiga	Dapagliflozin Propanediol	24	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	24	suppressed
Paroxetine Hcl	Paroxetine Hcl	24	suppressed
Trazodone Hcl	Trazodone Hcl	24	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	23	suppressed
Valsartan	Valsartan	23	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	22	20
Folic Acid	Folic Acid	22	suppressed
Ropinirole Hcl	Ropinirole Hcl	22	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	22	suppressed
Incruse Ellipta	Umeclidinium Bromide	21	suppressed
Levetiracetam	Levetiracetam	21	suppressed
Baclofen	Baclofen	19	suppressed
Humalog Kwikpen U-100	Insulin Lispro	19	suppressed
Citalopram Hbr	Citalopram Hydrobromide	18	suppressed
Enalapril Maleate	Enalapril Maleate	18	suppressed
Roflumilast	Roflumilast	18	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	18	16
Triamcinolone Acetonide	Triamcinolone Acetonide	18	11
Oxybutynin Chloride Er	Oxybutynin Chloride	17	suppressed
Ramipril	Ramipril	17	suppressed
Breo Ellipta	Fluticasone/Vilanterol	16	suppressed
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	16	suppressed
Diclofenac Sodium	Diclofenac Sodium	16	suppressed
Mupirocin	Mupirocin	16	suppressed
Entresto	Sacubitril/Valsartan	15	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	15	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	15	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Metronidazole	Metronidazole	14	suppressed
Trulicity	Dulaglutide	14	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	13	suppressed
Digoxin	Digoxin	13	suppressed
Klor-Con M20	Potassium Chloride	13	suppressed
Mounjaro	Tirzepatide	13	suppressed
Novolog Flexpen	Insulin Aspart	13	suppressed
Tradjenta	Linagliptin	13	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Hydrocortisone	Hydrocortisone	12	suppressed
Nexium	Esomeprazole Magnesium	12	suppressed
Temazepam	Temazepam	12	suppressed
Azithromycin	Azithromycin	11	suppressed
Bumetanide	Bumetanide	11	suppressed
Donepezil Hcl	Donepezil Hcl	11	suppressed
Fenofibrate	Fenofibrate	11	suppressed
Fluconazole	Fluconazole	11	suppressed
Terazosin Hcl	Terazosin Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error